Very curious that this came just a couple weeks after they announced licensing their first drug compound (using data from the test kits?) to the Spanish firm Almirall [0,1].
Anybody have any ideas about this? Why would they slow down the "growth and scaling efforts" (as the cnbc article claims) even despite lower-than expected sales, when the data from kits is what gives them the unique(?) capability to discover novel drug compounds at a massively reduced cost compared to traditional pharma companies.
[0] https://www.bloomberg.com/news/articles/2020-01-09/23andme-l...